v3.26.1
Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Information    
Number of operating segments | segment 1  
Number of reportable segments | segment 1  
Total revenue $ 132,865 $ 3,120
Income (loss) from operations 61,504 (35,425)
Other income (expense), net (4,722) (2,942)
Income (loss) before income taxes 56,782 (38,367)
Income tax expense 3,920 0
Net income (loss) and comprehensive income (loss) 52,862 (38,367)
Product sales, net    
Segment Information    
Total revenue 129,881  
Cost of revenue 11,079  
Service revenue, net    
Segment Information    
Total revenue 2,984 3,120
Cost of revenue 773 1,517
Single reportable segment    
Segment Information    
Total revenue 132,865 3,120
Total program expenses 21,661 13,177
Non-program expenses 6,197 3,770
Personnel, including stock-based compensation 31,651 20,081
Income (loss) from operations 61,504 (35,425)
Other income (expense), net (4,722) (2,942)
Income (loss) before income taxes 56,782 (38,367)
Income tax expense 3,920  
Net income (loss) and comprehensive income (loss) 52,862 (38,367)
Single reportable segment | Product sales, net    
Segment Information    
Total revenue 129,881  
Cost of revenue 11,079  
Single reportable segment | Service revenue, net    
Segment Information    
Total revenue 2,984 3,120
Cost of revenue 773 1,517
Single reportable segment | YUTREPIA    
Segment Information    
Total program expenses 15,888 9,758
Single reportable segment | L606    
Segment Information    
Total program expenses 5,822 3,268
Single reportable segment | Generic Treprostinil    
Segment Information    
Total program expenses $ (49) $ 151